BioNTech

BioNTech is a pharmaceutical company that develops and commercializes mRNA and immunotherapies for the treatment of cancer disease. Read more

Ugur Sahin's photo - Co-Founder & CEO of BioNTech

Co-Founder & CEO

Ugur Sahin

CEO Approval Rating

97/100

Founded:

2008

Status:

PublicIndependent CompanyNASDAQBNTX

BIONTECH TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Moderna is the top competitor of BioNTech. Moderna is headquartered in Cambridge, Massachusetts, and was founded in 2010. Moderna competes in the Biotechnology field. Moderna generates 462% the revenue of BioNTech.

Inovio is perceived as one of BioNTech's biggest rivals. Inovio was founded in Plymouth Meeting, Pennsylvania} in 1979. Like BioNTech, Inovio also operates in the Biotechnology industry. Compared to BioNTech, Inovio generates $584.7M less revenue.

China National Pharmaceutical Group Co Ltd is seen as one of BioNTech's top competitors. China National Pharmaceutical Group Co Ltd is a Private company that was founded in Haidian District, Beijing Municipality in 2003. Like BioNTech, China National Pharmaceutical Group Co Ltd also works within the Pharmaceuticals industry. China National Pharmaceutical Group Co Ltd has 153,422 more employees vs. BioNTech.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Immatics a competitor of BioNTech?

BioNTech Quarterly and Annual Revenue

Coming soon for BioNTech!

Annual Revenue

$591.1M

BioNTech's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 4.3B.

BioNTech Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Neon Therapeutics, Inc.

Jan 2020

Source »
$67M
NEON is a biopharmaceutical firm that develops and commercializes novel cell therapies for the treatment of cancer.

-

Antibody Business and Infrastructure of MabVax Therapeutics Holding, Inc

May 2019

Source »
undisclosed
-

These are all the companies that BioNTech has acquired. BioNTech has acquired 2 companies and its latest acquisition was Neon Therapeutics, Inc. in Jan 2020. NEON is a biopharmaceutical firm that develops and commercializes novel cell therapies for the treatment of cancer.

BioNTech Funding History

Since BioNTech was founded in 2008, it has participated in 8 rounds of funding. In total BioNTech has raised $1.6B. BioNTech's last funding round was on Sep 2020 for a total of $445.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Grant
Sep 2020
$445M
-
Debt
Jun 2020
$112M
IPO
Oct 2019
$150M

Equity
Sep 2019
$55M
Series B
Jul 2019
$325M

Since BioNTech was founded in 2008, it has participated in 8 rounds of funding. In total BioNTech has raised $1.6B. BioNTech's last funding round was on Sep 2020 for a total of $445.0M

BioNTech Investments

No recent investments found related to BioNTech

These are all the companies that BioNTech has invested in. BioNTech has invested 2 companies and its latest investment was Neon Therapeutics, Inc. in Jan 2020. NEON is a biopharmaceutical firm that develops and commercializes novel cell therapies for the treatment of cancer.

BioNTech News

June 10, 2021DailyBusiness

Pharma giants supply 500m Covid vaccine doses to poor

Read More The post Pharma giants supply 500m Covid vaccine doses to poor appeared first on Daily Busi... See more »
June 10, 2021MarketScreener

By Erika Solomon in Berlin and Sam Fleming in Brussels (Form 6-K)

(marketscreener.com) By Erika Solomon in Berlin and Sam Fleming in Brussels BioNTech is planning a pu... See more »
June 10, 2021Endpoints News

Exelead inks deal to manufacture lipid nanoparticles for Pfizer/BioNTech vaccine

For the two leading Covid-19 vaccines, mRNA is the star of the show - and the microscopic lipids used... See more »
June 9, 2021Clinical Trials Arena

Pfizer trials lower Covid-19 vaccine dose in children

The post Pfizer trials lower Covid-19 vaccine dose in children appeared first on Clinical Trials Aren... See more »
May 30, 2021MarketScreener

and Biontech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents

(marketscreener.com) NEWYORKandMAINZ,GERMANY,May 28, 2021 - Pfizer Inc. and BioNTechSE today announce... See more »
May 24, 2021MarketScreener

Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults

(marketscreener.com) Pfizer Inc. today announced that the first enrolled subjects have received their... See more »
May 22, 2021Pharmabiz

UK MHRA approves new storage conditions for Pfizer/BioNTech Covid19 vaccine from 5 to 31 days

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved new storage conditions... See more »

BioNTech Press Releases

March 11, 2021StreetInsider

Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared

Dramatically lower COVID-19 disease incidence rates observed in individuals fully vaccinated with the... See more »
January 15, 2021Cision Canada

Amenida Seniors Community Residents Receive First Dose of COVID-19 Vaccine

/CNW/ - On Thursday January 14, 2021, Amenida Seniors Community received their first supply of the Pf... See more »
May 12, 2020StreetInsider

BioNTech Announces First Quarter 2020 Financial Results and Corporate Progress

Global Phase 1/2 clinical trial for BNT162 vaccine program to prevent COVID-19 infection in dose esca... See more »
March 20, 2020StreetInsider

German Companies at the Heart of Coronavirus Vaccine Efforts

BERLIN, March 20, 2020 /PRNewswire/ -- German companies CureVac and BioNTech were both in the headlin... See more »
June 17, 2019Business Wire

BioNTech and Genmab Initiate First-In-Human Phase I/IIa Trial of Bispecific Antibody DuoBody®-PD-L1x4-1BB in Solid Tumors

MAINZ, Germany--(BUSINESS WIRE)--BioNTech SE, a clinical-stage biotechnology company focused on patie... See more »
August 1, 2018PR Newswire

BioNTech and SMP to evaluate SMP's next generation technology for BioNTech products

ORTE, DATUM AND AUBURN, Ala., Aug. 1, 2018 /PRNewswire/ -- BioNTech AG ("BioNTech") and SiO2 Medical ... See more »
January 4, 2018ECONOTIMES

BioNTech Secures USD 270 Million in Series A Financing

BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy,... See more »

Social Media

BioNTech Headquarters

An der Goldgrube 12

Mainz, Rhineland-Palatinate55131

49-6131-9084-0

Driving Directions »

Trending Companies

BioNTech Summary

ABOUT

Overview

BioNTech is a pharmaceutical company that develops and commercializes mRNA and immunotherapies for the treatment of cancer disease. BioNTech was founded in 2008. BioNTech's headquarters is located in Mainz, Rhineland-Palatinate, DE 55131. It has raise...

CEO

BioNTech's Co-Founder & CEO, Ugur Sahin, currently has an approval rating of 97%. BioNTech's primary competitors are Moderna, Inovio & China National Pharmaceutical Group Co Ltd.

Frequently Asked Questions about BioNTech

  1. When was BioNTech founded?

    BioNTech was founded in 2008
  2. Who is BioNTech's CEO?

    BioNTech's CEO is Ugur Sahin
  3. How much revenue does BioNTech generate?

    BioNTech generates $591.1M in revenue
  4. How much funding does BioNTech have?

    BioNTech has historically raised $1.6B in funding
  1. Where is BioNTech's headquarters?

    BioNTech's headquarters is in Mainz Rhineland-Palatinate, DE
  2. How many employees does BioNTech have?

    BioNTech has 2,200 employees
  3. What sector does BioNTech operate in?

    BioNTech is in Biotechnology, Pharmaceuticals
  4. Who are BioNTech's competitors?

    BioNTech's top competitors are Moderna, Inovio, China National Pharmaceutical Group Co Ltd